Clinical Trial Update: Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating pembrolizumab with mogamulizumab in advanced-stage, relapsed/refractory cutaneous T-cell lymphoma, including mycosis fu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Mycosis Fungoides
• Sézary Syndrome

Drugs mentioned

• Mogamulizumab (mogamulizumab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome | Phase 2 | Status: RECRUITING